Scandinavian ChemoTech Q3 2023: Initial comments - Redeye

Redeye provides an initial comment on the Q3 2023 report from Scandinavian ChemoTech. The quarter showed stronger sales than forecasted, along with improved cost control. The company recently announced a preferred rights issue of SEK14.9m that is secured to 40%. We will not make any adjustments to the fair value range until more tangible information is available on the financing situation.

Länk till analysen i sin helhet: https://www.redeye.se/research/947358/scandinavian-chemotech-q3-2023-initial-comments?utm_source=finwire&utm_medium=RSS